Regulation of skeletal muscle protein turnover during sepsis

Current Opinion in Clinical Nutrition and Metabolic Care

Volumn 1, Issue 2, 1998, Pages 217-224

  Vary, Thomas C ^a  

^a PENN STATE COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; HORMONE; MUSCLE PROTEIN;

ANIMAL; HOMEOSTASIS; HUMAN; METABOLISM; PHYSIOLOGY; REVIEW; SEPSIS; SKELETAL MUSCLE;

ANIMALS; CYTOKINES; HOMEOSTASIS; HORMONES; HUMANS; MUSCLE PROTEINS; MUSCLE, SKELETAL; SEPSIS;

EID: 0032010177     PISSN: 13631950     EISSN: None     Source Type: Journal    
DOI: 10.1097/00075197-199803000-00013     Document Type: Article

References (56)

1. Cerra FB, Siegel JH, Coleman B, Border JR, McMenamy RR. Septic autocannibalism: a failure of exogenous nutritional support. Ann Surg 1980; 192:570-580.
2. Tjoder I, Essen P, Therne A, Garlick P, Wernerman J, McNurlan MA. Muscle protein synthesis decreases 24 hours after abdominal surgey irrespective of total parenteral nutrition. J Parent Enteral Nutr 1996; 20:135-138.
3. Wilmore DW. Catabolic illness, strategies for enhancing recovery. N Engl J Med 1991; 325:695-702.
4. Bower RH, Cerra FB, Bershadsky B, Licari JJ, Hoyt DB, Jensen GJ, et al. Early enteral administration of a formula (Impact) supplemented with arginine, nucleotides, and fish oil in intensive care unit patients: results of a multicenter, prospective, randomized, clinical trial. Crit Care Med 1995; 23:436-449.
5. Moore FA, Moore EE, Kudsk KA, Brown RO, Bower RH, Koruda MJ, et al. Clinical benefits of an immune-enhancing diet for early postinjury enteral feeding. J Trauma 1994; 37:607-615.
6. Vary TC, Kimball SR, Cooney RN. Regulation of skeletal muscle protein turnover during sepsis: mechanisms and mediators. Shock 1997; 7:1-16.
7. Tiao G, Lieberman M, Fischer JE, Hasseigren P-O. Intracellular regulation of protein degradation during sepsis is different in fast- and slow-twitch muscle. Am J Physiol 1997; 272:R849-R856.
8. Vary TC, Owens EL, Beers JK, Verner K, Cooney RN. Sepsis inhibits synthesis of myofibrillar and sarcoplasmic proteins: modulation by interleukin-1 receptor anatgonist. Shock 1996; 6:13-18.
9. Hasseigren PO, James JH, Benson DW, Angeras U, Hiyama DT, Shujun LI, Fisher JE. Total and myofibrillar protein breakdown in different types of rat skeletal muscle: effects of sepsis and regulation by insulin. Metabolism 1989; 38:634-640.
10. Frost RA, Lang CH, Gelato MC. Transient exposure of human myoblasts to tumor necrosis factor-α inhibits serum and insulin-like growth factor-1 stimulated protein synthesis. Endocrinology 1997; 138:4153-4159. Addition of TNF was shown to modulate protein synthesis in myoblasts in culture. The effects of TNF were observed over a relatively long period, indicating that TNF may have effects that last beyond the period where their concentration is increased.
11. Peraldi P, Hotamisligil GS, Buurmant WA, White MF, Spiegelman BM. Tumor necrosis factor (TNF)-α inhibits insulin signaling through stimulation of the p55TNF receptor and activation of sphingomyelinase. J Biol Chem 1996; 271:13018-13022.
12. Wolfe RR. Herman Lecture. Relation of metabolic studies to clinical nutrition - the example of burn injury. Am J Clin Nutr 1996; 64:800-808.
13. Kimball SR, Vary TC, Jefferson LS. Regulation of protein synthesis by insulin. Ann Rev Physiol 1994; 56:321-348.
14. Vary TC, Jurasinski C, Kimball SR. Reduced 40S initiation complex formation in skeletal muscle during sepsis. Mol Cell Biochem 1997 (in press). By examining the incorporation of [35S]methionine into 43S preinitiation complexes as isolated on CsCI density grardients, a direct effect of sepsis on one of the early steps in peptide-chain initiation was demonstrated. These studies therefore identify one biochemical locus responsible the inhibition of protein synthesis in sepsis.
15. Kimball S, Vary TC, Jefferson LS. Age-dependent decrease in the amount of eukaryotic initiation factor 2 in various rat tissues. Biochem J 1992; 286:263-268.
16. Vary TC, Jurasinski CV, Karinch AM, Kimball SR. Regulation of eukaryotic initiation factor 2 expression during sepsis. Am J Physiol 1994; 266:E193-E201.
17. Voisin L, Gray K, Jurasinski CV, Flowers KM, Kimball SR, Jefferson LS, Vary TC. Altered expression of eukaryotic initiation factor 2B in skeletal muscle during sepsis. Am J Physiol 1996; 270:E43-E50. These studies showed that sepsis, but not sterile inflammtion cause expression of elF-2B protein to be diminished. The decrease in protein paralleled a similar reduction in the mRNA suggesting that the protein content is regulated by mRNA expression. No alteration in elF-2B activity was observed in heart, a tissue where protein synthesis is not affected by sepsis. The depletion of elF-2B protein provides in part a biochemical reason for reduced elF-2B activity in fast-twitch muscle during sepsis.
18. Vary TC, Voisin L, Cooney RN. Regulation of peptide-chain initiation during sepsis by interleukin-1 receptor antagonist. Am J Physiol 1996; 271:E513-E520. By using a specific inhibitor of IL-1, the authors were able to demonstrate that prevention of the fall in protein synthesis with this compound was attributed to a maintanence of elF-2B protein and mRNA at levels observed in control individuals.
19. Juransinski CV, Kilpatrick L, Vary TC. Amrinone prevents muscle protein wasting during chronic sepsis. Am J Physiol 1994; 268:E636-E641.
20. Breuille D, Farge MC, Rose R, Arnal M, Obled C. Pentoxyfylline decreases the body weight loss and muscle protein wasting characteristic of sepsis. Am J Physiol 1993; 265:E660-E666.
21. Mitch WE, Goldberg AL. Mechanism of muscle wasting. Role of ubiqutin-proteasome pathway. N Engl J Med 1996; 335:1897-1905.
22. Hasselgren P-O, Fisher JE. The ubiquitin-proteasome pathway: a review of a novel intracellular mechanism of muscle protein breakdown during sepsis and other catabolic conditions. Ann Surg 1997; 225:307-316.
23. Argilles JM, Lopez-Soriano FJ. The ubiquitin-dependent proteolytic pathway in skeletal muscle: its role in pathological states. Trends Pharmacol Sci 1996; 17:223-226.
24. Tiao G, Fagan JM, Samuels N, James JH, Hudson K, Lieberman M, et al. Sepsis stimulates non-lysosomal, energy-dependent proteolysis and increases ubiquitin mRNA levels in skeletal muscle. J Clin Invest 1994; 94:2255-2264.
25. Tiao G, Fagan JM, Lieberman M, Fischer JE, Hasselgren P-O. Sepsis increases proteasome proteolysis and mRNA levels for proteasome subunit RC3 in skeletal muscle. Surg Forum 1995; 46:10-12.
26. Tiao G, Wang JJ, Meyer TA, Luchette FA, Fischer JE, Hasselgren P-O. Sepsis is associated with increased mRNAs of the ubiquitin-proteasome proteolytic pathway in human skeletal muscle. J Clin Invest 1997; 99:163-168. These observation suggest that the changes observed in the ubiquitin-proteasome pathway in animal models are also present in skeletal muscle from human septic patients.
27. 2+-activated, and ubiquitin-proteasome proteolytic pathways. J Clin Invest 1996;97:1610-1617. These investigations provide a quantitative index of the contribution of various components of the different proteolytic pathways to the overall rate of protein degradation after injection of live Escherichia coli.
28. Mansoor O, Beufrere B, Boirie Y, Rulliere C, Taillandier D, Aurousseau E, et al. Increased mRNA levels for components of the lysosomal, Ca2+-activated, and ATP-ubiquitin-dependent proteolytic pathways from head trauma patients. Proc Natl Acad Sci USA 1996; 93:2714-2718.
29. Stadtman E. Role of oxidized amino acids in protein breakdown and stability. Methods Enzymol 1995; 258:379-393.
30. Davies KJA, Goldberg AL. Oxygen radicals stimulate intracellular proteolysis and lipid peroxidation by independent mechanisms in erythrocytes. J Biol Chem 1987; 262:8220-8226.
31. Fagan JM, Ganguly M, Tiao G, Fischer JE, Hasselgren P-O. Sepsis increases oxidatively damaged proteins in skeletal muscle. Arch Surg 1996; 131:1326-1331.
32. Wing S, Goldberg AL. Glucocorticoids activate the ATP-ubiquitin-dependent proteolytic system in skeletal muscle during fasting. Am J Physiol 1993; 264:E668-E676.
33. Fischer JE, Hasselgren PO. Cytokines and glucocorticoids in the regulation of the 'hepto-skeletal muscle axis' in sepsis. Arch Surg 1991; 161:266-271.
34. Hall-Angeras M, Angeras U, Zamir O, Hasselgren PO, Fischer J. Effect of the glucocorticoid receptor RU 38486 on muscle protein breakdown in sepsis. Surgery 1991; 109:468-473.
35. Tiao G, Fagan JM, Roegner V, Lieberman M, Wang JJ, Fischer JE, Hasselgren P-O. Energy-ubiqutin-dependent muscle proteolysis during sepsis is regulated by glucocorticoids. J Clin Invest 1996; 97:339-348.
36. Auclair D, Garrel DR, Zerouala AC, Ferland LH. Activation of ubiquitin pathway in rat skeletal muscle by catabolic doses of glucocorticoids. Am J Physiol 1997; 272:C1007-C1016. Administration of dexamethasome to animals activated the ubiqutin pathway of proteolysis in rat skeletal muscle, providing additional evidence for a role of glucocorticoids in initiating the changes in proteolysis in sepsis.
37. Hong DH, Forsberg NE. Effects of dexamethasone on protein degradation and protease gene expression in rat L8 myotubes in culture. Mol Cell Endocrinol 1995; 108:199-209.
38. Zamir O, Hasselgren PO, O'Brien W, Thompson RC, Fischer JE. Muscle protein breakdown during endotoxemia in rats after treament with interleukin-1 receptor antagonist. Ann Surg 1992; 216:381-386.
39. Zamir O, Hasselgren PO, O'Brien W, Von Allmen D, Fischer JE. In vivo administration of IL-1α induces muscle proteolysis in normal and adrenalectomized rats. Metabolism 1993; 42:204-208.
40. Zamir O, Hasselgren PO, Higashiguchi T, Frederick JA, Fischer JE. Tumor necrosis factor (TNF) and interleukin-1 (IL-1) induce muscle proteolysis through different mechanisms. Mediat Inflam 1992; 1:247-250.
41. Goodman MN. Interleukin-6 induces skeletal muscle protein breakdown in rats. Proc Soc Exp Biol Med 1994; 205:182-185.
42. Ebisui C, Tsujinaka T, Morimoto T, Kan K, Ijima S, Yano M, et al. Interleukin-6 induces proteolysis by activating intracellula cathepsin B and L in C2C12 myotubes. Clin Sci 1995; 89:431-439.
43. Tsujinaka T, Fujita J, Ebisui C, Yano M, Kominami E, Suzuki K, et al. Interleukin-6 antibody inhibits muscle atrophy and modulates proteolytic systems in interleukin-6 transgenic mice. J Clin Invest 1996; 97:244-249.
44. Vera-Thorbech R, Ruz-Reguena E, Guerro-Fernandez JA. Effects of human growth hormone in catabolic state after surgical trauma. Hormone Res 1996; 45:55-60.
45. Dann MS, Lange LA, Jacobs LA. Insulin-like growth factor 1 production is inhibited in human sepsis. Arch Surg 1988; 123:1409-1414.
46. Lund PK. Insulin-like growth factor 1: molecular biology and relevance to tissue-specific expression and action. Rec Prog Hormone Res 1994; 49:125-148.
47. Jones JI, Clemmons DR. Insulin-like growth factors and their binding proteins: biological actions. Endocr Rev 1995; 16:3-34.
48. Rechter. MM. Insulin-like growth factor binding proteins. Vitam Horm 1993; 47:1-113.
49. Fan J, Molina PE, Gelato MC, Lang CH. Differential tissue regulation of insulin-like growth factor-I content and binding proteins after endotoxin. Endocrinology 1994; 134:1685-1692.
50. Lang CH, Fan J, Cooney R, Vary TC. Interleukin-1 receptor antagonist attenuates sepsis-induced alterations in insulin-like growth factor system and protein synthesis. Am J Physiol 1996; 270:E430-E437. These studies provide evidence for a role of IL-1 as an endogenous mediator of the sepsis-induced changes in the IGF-I system, and suggest that the accompanying changes in muscle protein synthesis are partially mediated by decreases in IGF-I.
51. Wojnar MM, Fan J, Frost RA, Gelato MC, Lang CH. Alterations in the insulin-like growth factor system in trauma patients. Am J Physiol 1995; 268:R970-R977.
52. Lang CH, Pollard V, Fan J, Traber LD, Frost RA, Gelato MC, Prough DS. Acute alterations in growth hormone-insulin-like growth factor axis in humans injected with endotoxin. Am J Physiol 1997; 273:R371-R378.
53. Li YH, Fan J, Lang CH. Differential role of glucocorticoids in mediating endotoxin-induced changes in IGF-I and IGFBP-I. Am J Physiol 1997; 272:R1990-R1997. These studies show that inhibition of glucocorticoids with a specific receptor antagonist failed to prevent lipopolysaccharide-induced decrease in IGF-I content in muscle.
54. Dickerson RN, Manzo CB, Charland SL, Settle RG, Stein TP, Kuhl DA, Rajter J-J. The effects of insulin-like growth factor-I on protein metabolism and hepatic response to endotoxin in parenterally fed rats. J Surg Res 1995; 58:260-266.
55. Jurasinski CV, Vary TC. Insulin-like growth factor-I accelerates protein synthesis in skeletal muscle during sepsis. Am J Physiol 1995; 269:E977-E981.
56. Fang C-H, Li BG, James JH, Fischer JE, Hasseigren P-O. Cytokines block the effects of insulin-like growth factor-I (IGF-I) on glucose uptake and lactate production in skeletal muscle but do not influence IGF-I-induced changes in protein turnover. Shock 1997; 8:362-367.